MichaelADansoMD

PubMed

• Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
  Al Sukhun, S., Temin, S., Barrios, C., Antone, N., Guerra, Y., Chavez-MacGregor, M., Chopra, R., Danso, M., Gomez, H., Homian, N., Kandil, A., Kithaka, B., Koczwara, B...> ;JCO Global Oncology. 2024 Jan 1
• 2 citations
  Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
  Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Joanne L Blum, Lida A Mina, Raymond Brig, Michael Danso, Yuan Yuan, Antonello Abbattista, Kay Noonan, ...> ;The Oncologist. 2023 Oct 3
• 13 citations
  Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.
  Antoinette R Tan, Gail S Wright, Anu R Thummala, Michael A Danso, Lazar Popovic, Timothy J Pluard, Hyo S Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A Richards...> ;Clinical Cancer Research. 2022 Feb 15
• 23 citations
  Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or H...
  Beverly Moy, R. Bryan Rumble, Steven E. Come, Nancy E. Davidson, Angelo Di Leo, Julie R. Gralow, Gabriel N. Hortobagyi, Douglas Yee, Ian E. Smith, Mariana Chavez-MacGr...> ;Journal of Clinical Oncology. 2021 Jul 29
• 8 citations
  Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
  Bora Lim, David Potter, Mohamad Adham Salkeni, Paula Silverman, Tufia C. Haddad, Frédéric Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues ...> ;Clinical Cancer Research. 2021 Apr 5
• 17 citations
  Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
  Joyce O'Shaughnessy, Kristi McIntyre, Sharon Wilks, Ling Ma, Margaret Block, David Andorsky, Michael A. Danso, Tracy Locke, Amy Scales, Yunfei Wang> ;JAMA Network Open. 2021 Apr 1
• 16 citations
  Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
  Maitri Kalra, Yan Tong, David R. Jones, Thomas J. Walsh, Michael A. Danso, Cynthia X. Ma, Paula Silverman, Mary Claire King, Sunil Badve, Susan M. Perkins, Kathy D. Mi...> ;NPJ Breast Cancer. 2021 Mar 22
• 140 citations
  Antiemetics: ASCO Guideline Update.
  Paul J. Hesketh, Mark G. Kris, Ethan Basch, Kari Bohlke, Sally Y. Barbour, Rebecca Clark-Snow, Michael A. Danso, Kristopher Dennis, L. Lee Dupuis, Stacie B. Dusetzina,...> ;Journal of Clinical Oncology. 2020 Jul 13
• 63 citations
  Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
  Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso, Lazar Popovic, Timothy J. Pluard, Hyo S Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A. Richa...> ;The Lancet. Oncology. 2019 Nov 1
• 30 citations
  Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
  Aditya Bardia, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael A. Danso, Haythem Ali, Kimberly L. Blackwell, Lisa A. Carey, Joel R. Eisner, Edwina Baskin-Bey, Ti...> ;Breast Cancer Research and Treatment. 2018 May 9
• 462 citations
  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.
  Paul J Hesketh, Mark G Kris, Ethan Basch, Kari Bohlke, Sally Y Barbour, Rebecca Anne Clark-Snow, Michael A Danso, Kristopher Dennis, L Lee Dupuis, Stacie B Dusetzina, ...> ;Journal of Clinical Oncology. 2017 Oct 1
• 42 citations
  The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice
  Natalie B. Simon, Michael A. Danso, Thomas Alberico, Ethan Basch, Antonia V. Bennett> ;Quality of Life Research. 2017 Jun 29
• 27 citations
  Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Ran...
  Denise A. Yardley, James Reeves, E. Claire Dees, Cynthia R. C. Osborne, Devchand Paul, Foluso O. Ademuyiwa, Hatem Soliman, Troy Guthrie, Jay Andersen, Lea Krekow, Jana...> ;Clinical Breast Cancer. 2016 Dec 1
• 134 citations
  Antiemetics: American Society of Clinical Oncology Focused Guideline Update
  Paul J. Hesketh, Kari Bohlke, Gary H. Lyman, Ethan Basch, Maurice J. Chesney, Rebecca Clark-Snow, Michael A. Danso, Karin Jordan, Mark R. Somerfield, Mark G. Kris> ;Journal of Clinical Oncology. 2016 Sep 19
• 203 citations
  Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
  Joyce O'Shaughnessy, Lee S. Schwartzberg, Michael A. Danso, Kathy D. Miller, Hope S. Rugo, Marcus Neubauer, Nicholas J. Robert, Beth A. Hellerstedt, Mansoor N. Saleh, ...> ;Journal of Clinical Oncology. 2014 Oct 27
• 189 citations
  Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical On...
  Ann H. Partridge, R. Bryan Rumble, Lisa A. Carey, Steven E. Come, Nancy E. Davidson, Angelo Di Leo, Julie R. Gralow, Gabriel N. Hortobagyi, Beverly Moy, Douglas Yee, S...> ;Journal of Clinical Oncology. 2014 Oct 10
• 55 citations
  Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling
  Frankie A. Holmes, Virginia Espina, Lance A. Liotta, Yasir Nagarwala, Michael A. Danso, Kristi McIntyre, Cynthia Osborne, Thomas Anderson, Lea Krekow, Joanne L. Blum, ...> ;BMC Research Notes. 2013 Dec 5
• 468 citations
  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
  Ayca Gucalp, Sara M. Tolaney, Steven J. Isakoff, James N. Ingle, Minetta C. Liu, Lisa A. Carey, Kimberly L. Blackwell, Hope S. Rugo, Lisle Nabell, Andres Forero, Vered...> ;Clinical Cancer Research. 2013 Oct 1
• 521 citations
  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
  Ethan Basch, Ann Alexis Prestrud, Paul J Hesketh, Mark G Kris, Petra C Feyer, Mark R Somerfield, Maurice Chesney, Rebecca Anne Clark-Snow, Anne Marie Flaherty, Barbara...> ;Journal of Clinical Oncology. 2011 Nov 1
• HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515).
  Lin NU, Danso MA, David AK, Muscato JJ, Ellis CE, Lahiri S, Sessa T, Nagarwala YM, Winer E> ;J. Clin. Oncol.. 2011-05-20
• Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer...
  Holmes FA, Nagarwala YM, Espina VA, Liotta LA, Danso MA, Gallagher RI, McIntyre K, Osborne CRC, Mahoney JM, Florance AM, Anderson TC, O'Shaughnessy J> ;J. Clin. Oncol.. 2011-05-20
• A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
  O'Shaughnessy J, Schwartzberg LS, Danso MA, Rugo HS, Miller K, Yardley DA, Carlson RW, Finn RS, Charpentier E, Freese M, Gupta S, Blackwood-Chirchir A, Winer EP> ;J. Clin. Oncol.. 2011-05-20
• 58 citations
  Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic bre...
  Alison Conlin, Andrew D. Seidman, Ariadne M. Bach, Diana Lake, Maura N. Dickler, Gabriella D'Andrea, Tiffany A. Traina, Michael A. Danso, Adam Brufsky, Mansoor N. Sale...> ;Clinical Breast Cancer. 2010 Aug 1
• Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer.
  Danso MA, Blum JL, Robert NJ, Krekow L, Rotche R, Smith DA, Richards P, Anderson T, Richards DA, O'Shaughnessy J> ;J. Clin. Oncol.. 2008-05-20
• 426 citations
  An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
  Ashley S. Doane, Michael A. Danso, Priti Lal, M. Donaton, Liying Zhang, Clifford A. Hudis, William L. Gerald> ;Oncogene. 2006 Jun 29
• Join now to see all